Theratechnologies Phase III HIV trial in ‘07
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Theratechnologies plans to start enrolling patients in a new Phase III trial evaluating its growth hormone-releasing factor analogue TH9507 for treatment of HIV-associated lipodystrophy in the first quarter of 2007. The company launched its Phase III program in March 2005 and began enrolling patients at 43 clinical sites in North America in June. Under an August special protocol assessment agreement, the firm is permitted to conduct a second trial to test an additional 400 patients in North America and Europe to confirm results. The primary endpoint is an 8% reduction in visceral adipose tissue...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.